EUVIMEDOpdag EUVIMED
Übersichtsarbeit

A novel nbsp role for CD26 dipeptidyl peptidase IV as a therapeutic target

Kei Ohnuma, Ryo Hatano, Eriko Komiya, Haruna Otsuka, Takumi Itoh, Noriaki Iwao, Yutaro Kaneko, Taketo Yamada, Nam H Dang, Chikao Morimoto

Frontiers in Bioscience · 2018 · 23 (9) · 1754-1779

DOI: 10.2741/4671 ↗

At a glance

Übersichtsarbeit in Frontiers in Bioscience, 2018. Written by Kei Ohnuma and 9 co-authors. Institution: Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bu…. Cited 32 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

CD26 is a 110 kDa surface glycoprotein with intrinsic dipeptidyl peptidase IV activity that is expressed on numerous cell types and has a multitude of biological functions. The role of CD26 in immune regulation has been extensively characterized, with recent findings elucidating its linkage with signaling pathways and structures involved in T-lymphocyte activation as well as antigen presenting cell-T-cell interaction. In this paper, we will review emerging data on CD26-mediated immune regulation suggesting that CD26 may be an appropriate therapeutic target for the treatment of selected immune disorders as well as Middle East respiratory syndrome coronavirus. Moreover, we have had a long-standing interest in the role of CD26 in cancer biology and its suitability as a novel therapeutic target in selected neoplasms. We reported robust in vivo data on the anti-tumor activity of anti-CD26 monoclonal antibody in mouse xenograft models. We herein review significant novel findings and the early clinical development of a CD26-targeted therapy in selected immune disorders and cancers, advances that can lead to a more hopeful future for patients with these intractable diseases.

Subjects

MeSH terms (MEDLINE)

AnimalsAntibodies, MonoclonalDipeptidyl Peptidase 4HumansImmune System DiseasesLymphocyte ActivationNeoplasmsSignal TransductionT-Lymphocytes

Substances

Antibodies, MonoclonalDipeptidyl Peptidase 4

Authors and institutions

  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan, kohnuma@juntendo.ac.jp.
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Department of Hematology, Juntendo University Shizuoka Hospital, Nagaoka 1129, Izunokuni-city, Shizuoka 410-2295, Japan.
  • Y's AC Co., Ltd., 5-3-14, Toranomon, Minato-ku, Tokyo 105-0001, Japan.
  • Department of Pathology, Keio University school of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
  • Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road-Box 100278, Room MSB M410A, Gainesville, FL 32610, U.S.A.

Cite

APA

Ohnuma, K., Hatano, R., Komiya, E., Otsuka, H., Itoh, T., Iwao, N., Kaneko, Y., Yamada, T., Dang, N. H., & Morimoto, C. (2018). A novel nbsp role for CD26 dipeptidyl peptidase IV as a therapeutic target. Frontiers in Bioscience, 23(9), 1754-1779. https://doi.org/10.2741/4671

Vancouver

Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, et al. A novel nbsp role for CD26 dipeptidyl peptidase IV as a therapeutic target. Frontiers in Bioscience. 2018;23(9):1754-1779. doi:10.2741/4671

BibTeX
@article{Ohnuma2018,
  author = {Ohnuma, Kei and Hatano, Ryo and Komiya, Eriko and Otsuka, Haruna and Itoh, Takumi and Iwao, Noriaki and Kaneko, Yutaro and Yamada, Taketo and Dang, Nam H and Morimoto, Chikao},
  title = {A novel nbsp role for CD26 dipeptidyl peptidase IV as a therapeutic target},
  journal = {Frontiers in Bioscience},
  year = {2018},
  volume = {23},
  number = {9},
  pages = {1754--1779},
  doi = {10.2741/4671}
}
Start for free →